Lv3
330 积分 2023-11-18 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
25天前
已完结
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade
1个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
2个月前
已完结
Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers
3个月前
已关闭
A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro
5个月前
已完结
Intratumoral expression analysis reveals that OX40 and TIM‑3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer
5个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
5个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
5个月前
已完结
Update on the pathophysiology and treatment of primary Sjögren syndrome
5个月前
已完结
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics
5个月前
已完结
皖公网安备34019202002308
